

CLINICAL TRIALS WATCH

ACCESSIBLE EASY READ INFORMATION ON:

ALZEVIT STUDY

ALZEVIT study

1. Study Information

Name of the study	ALZEVIT: A nationwide decentralized digital cohort for population APOE genotyping, longitudinal characterization of APOE ε4/ε4 trajectories, and trial-readiness for precision prevention in early Alzheimer's disease
Study sponsor	Firalis SAS
Phase	Not applicable – prevention strategies for Alzheimer's disease

2. Information about participating in the study

What are the researchers trying to find out?	• The purpose of the study is to create the first French national APOE registry, accessible online, straightforward, and based on a saliva sample taken at home. This will address the need for early identification of individuals at risk for late-onset Alzheimer's disease for precision prevention in Alzheimer's disease.
How long will the study last?	• Up to 2 years
What your involvement will entail?	• During the study, participants will be asked to complete online questionnaires (risk-factor and cognitive assessments) • To provide a home-collected saliva sample for APOE genotyping • To complete some laboratory tests (e.g., blood test, urine) • Some participants will be asked to complete additional tests (accessing clinical and cognitive functions) and brain scans (MRI). Further information on the procedures, tests and visits can be obtained from the study team.

3. Who can participate in this study?

Who can participate in the study?	To take part in the study, participants must: • Be 45 years old and older • Reside in France • Able to read and understand the study information in French or with the help of a legal representative • Be affiliated with the French national health insurance system · Have access to the internet and a valid email address • Self-collect and return a saliva sample using a provided kit.
Who cannot participate in the study?	Exclusion criteria include: • Participants younger than 45 years at the time of consent. • Inabilities to read or understand French • Cognitive impairments, severe dementia or psychiatric conditions • Substance use disorder (alcohol or drug dependence) within the past 24 months • Enrolment in the ALZEVIT study or its pilot phase. The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

4. Where and when will the study be conducted?

European country involved in the trial	• France
Estimated start date of recruitment	September 2026

5. Further Information	
Clinicaltrials.gov identifier	NCT07679906
Study contact information	Alzevit@firalis.com
Link to full text	https://clinicaltrials.gov/study/NCT07679906
Link to study's website	https://alzevit.com/en/

- ✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) in September 2026.
- ✓ This document has been reviewed by the institution running this trial.